These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9161651)

  • 1. Interaction between quinupristin/dalfopristin and cyclosporine.
    Stamatakis MK; Richards JG
    Ann Pharmacother; 1997 May; 31(5):576-8. PubMed ID: 9161651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluconazole decreases cyclosporine dosage in renal transplanted dogs.
    Katayama M; Igarashi H; Fukai K; Tani K; Momota Y; Kamishina H; Tagawa M
    Res Vet Sci; 2010 Aug; 89(1):124-5. PubMed ID: 20137796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible interaction between intravenous azithromycin and oral cyclosporine.
    Page RL; Ruscin JM; Fish D; Lapointe M
    Pharmacotherapy; 2001 Nov; 21(11):1436-43. PubMed ID: 11714218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction.
    Sketris IS; Wright MR; West ML
    Pharmacotherapy; 1996; 16(2):301-5. PubMed ID: 8820476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
    Rostami Z; Einollahi B; Morshedi J; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
    Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
    Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinupristin and dalfopristin.
    Am J Health Syst Pharm; 1999 Dec; 56(24):2530-1. PubMed ID: 10613369
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline and cyclosporine interaction-an interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine.
    Srinivas NR
    Eur J Clin Pharmacol; 2009 May; 65(5):543-4. PubMed ID: 19224202
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy.
    Carver PL; Whang E; VandenBussche HL; Kauffman CA; Malani PN
    Pharmacotherapy; 2003 Feb; 23(2):159-64. PubMed ID: 12587804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.
    Rubinstein E; Prokocimer P; Talbot GH
    J Antimicrob Chemother; 1999 Sep; 44 Suppl A():37-46. PubMed ID: 10511396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations.
    Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO
    Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients.
    Jensen RA; Lal SM; Diaz-Arias A; James-Kracke M; Van Stone JC; Ross G
    ASAIO J; 1995; 41(3):M704-6. PubMed ID: 8573896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.
    Bleyzac N; Kebaili K; Mialou V; Bertrand Y; Goutelle S
    Ther Drug Monit; 2014 Dec; 36(6):724-9. PubMed ID: 24739665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple drug interactions with cyclosporine in a heart transplant patient.
    Zylber-Katz E
    Ann Pharmacother; 1995 Feb; 29(2):127-31. PubMed ID: 7756709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine trough level or 2-hour postdose level monitoring among kidney transplant recipients: Iranian practice.
    Einollahi B; Rostami Z; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):389-90. PubMed ID: 22976267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.